Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation
Latest investor presentation
Latest quarterly earnings
Latest quarterly earnings
Latest clinical presentation
Latest clinical presentation
Latest publications, posters & presentations
Our research
Annual report
Annual report
NASDAQ:NVAX
Loading data...
Stock details
Latest press releasesEvents & presentationReports & financialsSEC filingsStock details & analyst coverage
Stock details

Loading data...

 

Historical stock price

Analyst coverage
Mayank Mamtani
B. Riley FBR
Alec Stranahan, PhD
BofA Securities
Brendan Smith, PhD
TD Cowen
Vernon Bernardino
H.C. Wainwright & Co.
Roger Song, MD, CFA
Jefferies
Eric Joseph, PhD
JP Morgan

The analysts listed on this page follow Novavax. Please note that any opinions, estimates or forecasts regarding Novavax' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novavax or its management. Novavax does not by its reference above or distribution imply its endorsements of or concurrence with such information, conclusions or recommendations.

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more
Lisa Dunkle

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.
I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine
Governance documents
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription
Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.